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Control of intestinal stem cell fate: A novel
approach to treating diabetes
Gastric inhibitory polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1) are
incretins released from enteroendocrine
cells into the circulation in response to
ingested nutrients, such as glucose and
fat. GIP is secreted from K-cells in the
duodenum and upper small intestine,
and GLP-1 is secreted by L-cells in the
lower small intestine and colon. In addi-
tion to its glucose-dependent insulinotro-
pic effect, GLP-1 has other beneﬁcial
effects that help achieve targeted blood
glucose levels, such as inhibition of glu-
cagon secretion, delayed gastric emptying
and appetite suppression1. However,
both GLP-1 and GIP are rapidly
degraded and inactivated in vivo by
dipeptidyl peptidase-4 (DPP-4). Two
methodologies have been developed to
enhance the incretin effect as therapy
for diabetes, DPP-4 inhibitors and GLP-
1 receptor agonists resistant to cleavage
by DPP-4.
Another possible approach is enhance-
ment of endogenous GLP-1 secretion.
Severely obese patients with type 2 dia-
betes who undergo bariatric surgery
show signiﬁcant and rapid improvement
of glycemic control even up to complete
cure of diabetes. The underlying mecha-
nism of the dramatic improvement in
glycemic control observed in these
patients seems partly independent of
weight reduction, and is associated with
alterations in the secretion of enteroen-
docrine hormones, such as increased
plasma levels of GLP-1. As endogenous
GLP-1 concentrations are remarkably
increased 5–10-fold after bariatric sur-
gery2, the therapeutic potential of
enhancing endogenous GLP-1 secretion
is strongly suggested. However, no ideal
strategy to stimulate GLP-1 secretion has
been reported. Recently, Petersen et al.3
showed that blocking the NOTCH sig-
naling pathway with c-secretase inhibitor
in mouse and human intestinal orga-
noids increased the number of L-cells,
and augmented glucose-stimulated GLP-
1 secretion. Furthermore, in high-fat
diet-fed mice with impaired glucose tol-
erance, administration of c-secretase
inhibitor improved the early insulin
response to glucose, and restored glucose
tolerance in association with a signiﬁcant
increase in L-cell number and GLP-1
secretion.
Enteroendocrine cells arise from
pluripotent intestinal stem cells located
in intestinal crypts (Figure 1). The earli-
est cell fate decisions are regulated by
the NOTCH signaling pathway4. When
membrane-bound NOTCH receptor
interacts with ligand anchored in the
membrane of neighboring cells, an
intrinsic c-secretase cleaves the receptor,
releasing the NOTCH intracellular
domain (NICD). NICD translocates into
the nucleus, and stimulates the expres-
sion of hairy and enhancer of split 1.
Hairy and enhancer of split 1 has been
shown to repress expression of protein
atonal homolog 1 and neurogenin 3.
Atonal homolog 1 is the ﬁrst factor
known to be involved in endocrine spec-
iﬁcation, inducing cells to the secretory
lineages, goblet, paneth and enteroen-
docrine cells. Neurogenin 3 is expressed
in the precursor cell to all enteroen-
docrine cells, and loss of neurogenin 3
in mice results in a loss of most
enteroendocrine lineages. Thus, activa-
tion of NOTCH signaling induces
intestinal stem cells to differentiate into
absorptive epithelial cells, and blocking
the NOTCH signaling pathway increases
the number of cells differentiating into
enteroendocrine lineages including L-
cells.
L-cells secrete not only GLP-1, but also
oxyntomodulin and peptide YY, anorexic
hormones known to be involved in food
intake, energy expenditure and regulation
of glucose homeostasis. Therefore,
enrichment of L-cells might increase
these anorexic hormones, resulting in
appetite suppression and reduction in
bodyweight. However, repetitive treat-
ment with NOTCH inhibitor is toxic
and not suitable for continuous use to
reduce bodyweight.
Gamma-secretase inhibitor was found
to increase the number not only of L-cells,
but also of K-cells, which resulted in
increased GIP secretion. GIP has been
explored as a potential glucose-lowering
drug based on its glucose-dependent insu-
linotropic effect. It has been reported that
the insulinotropic action of GIP is
impaired in diabetic patients and is ame-
liorated as the glycemic condition is
improved5. Thus, GIP will have synergistic
effects with augmented GLP-1 signaling
after treatment with NOTCH inhibitor. In
contrast, studies of GIP receptor knockout
mice describe GIP as an obesity-promot-
ing factor in high-fat diet conditions, and
show that deletion of GIP receptor signal-
ing causes resistance to diet-induced
obesity6. Additionally, partial reduction of
GIP alleviates obesity, and lessens the
degree of insulin resistance without
exacerbating glucose tolerance under
high-fat diet conditions7. These ﬁndings
suggest that regulation of GIP secretion,
especially after fat intake, is a promising
therapeutic approach to obesity and type 2
diabetes, and GIP antagonists have been
proposed to improve insulin sensitivity by
preventing the development of obesity.
Because GIP exhibits not only an insulino-
tropic effect, but also an obesity-promoting
effect, it is still controversial whether or
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not enhanced GIP secretion after treat-
ment with NOTCH inhibitor contributes
to the improvement of metabolic condi-
tions, especially under high-fat diet
feeding.
The effect of NOTCH inhibition is not
selective for only L-cells and K-cells; other
enteroendocrine hormones might also be
increased, such as ghrelin, a representative
orexigenic hormone, and gastrin, which
stimulates gastric acid secretion. It is
therefore possible that increased appetite,
intractable peptic ulcer disease and other
adverse reactions could occur as a result
of increased enteroendocrine cells using
NOTCH inhibitor clinically. Regarding
the effects of NOTCH inhibition on
pancreatic b-cells, Petersen et al.3 showed
that treatment with NOTCH inhibitor for
two consecutive days had no direct effects
on insulin secretion, and that increased
insulin secretion and improved glucose
tolerance were mainly a result of
augmented GLP-1 release in NOTCH
inhibitor-treated mice. Previously, in vitro
analysis has shown that inhibition of
NOTCH signaling promotes differentia-
tion of embryonic pancreatic cells into
functional islet-like clusters and induces
dedifferentiated b-cell-derived cells into
redifferentiated, functional b-cells8. There
is as yet no demonstration of the effects
of long-term inhibition of NOTCH
signaling on islet morphology and
function in vivo, which is a critical issue
to be clariﬁed in the future.
NOTCH signaling plays an important
role in original development and determi-
nation of cell fate, and it is deregulated in
not only hematological malignancies, but
also in solid tumors9. Targeting of the
NOTCH signaling pathway as a treatment
for cancer is currently under develop-
ment. However, clinical development has
stagnated due to treatment-related toxici-
ties, especially gastrointestinal adverse
events, and by necessarily complex
optimizing processes for drug dosing
schedules. In such conditions, NOTCH
inhibitors may well not be available for
clinical application for the treatment of
diabetes in the near future. Identiﬁcation
of a more selective regulator of L-cell
development should be prioritized for
clinical application. Nevertheless, targeting
L-cell development and enrichment of
incretin-secreting cells could potentially
evolve as novel, effective therapeutics for
diabetes.
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Figure 1 | Schematic overview of enteroendocrine differentiation. Pluripotent intestinal stem cells located in intestinal crypts differentiate into all
four cell types present in the intestinal epithelium. NOTCH signaling promotes differentiation to the absorptive lineage by repressing protein atonal
homolog 1 (Atoh1) transcription. Atoh1 restricts cells to the secretory subset and neurogenic differentiation 1 restricts cells to the endocrine
lineage. CCK, cholecystokinin; GIP, gastric inhibitory polypeptide; GLP-1, glucagon-like peptide-1; Hes1, hairy and enhancer of split 1; NeuroD1,
neurogenic differentiation 1; Neurog3, neurogenin 3; PYY, peptide YY.
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